Trastuzumab emtansine API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Trastuzumab emtansine API 1018448-65-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Trastuzumab emtansine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Trastuzumab emtansine
- Synonyms:
- Ado-trastuzumab emtansine , Ado-trastuzumab , Trastuzumab emtansine , Trastuzumab-DM1
- Cas Number:
- 1018448-65-1
- DrugBank number:
- DB05773
- Unique Ingredient Identifier:
- SE2KH7T06F
About Trastuzumab emtansine
Here is a short description about Trastuzumab emtansine. Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.
